S5G Therapeutics Inc
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
- National Institutes of Health$313K1
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
S5G THERAPEUTICS INC — Grant R43EY037617
NOVEL THERAPEUTIC FOR PREVENTING FUCHS ENDOTHELIAL CORNEAL DYSTROPHY - PROJECT SUMMARY/ABSTRACT FUCHS ENDOTHELIAL CORNEAL DYSTROPHY (FECD) IS A POLYGENIC DISEASE THAT AFFECTS 6.1 MILLION AMERICANS OVER 40 YEARS OF AGE. FECD IS THE LEADING INDICATION FOR CORNEAL TRANSPLANT SURGERY IN THE U.S. ALTHOUGH THE CONDITION CAN BE DIAGNOSED EARLY, IT REQUIRES CORNEAL SURGERY BECAUSE NO AVAILABLE THERAPY PREVENTS DISEASE PROGRESSION. UNFORTUNATELY, THE AVAILABILITY OF DONOR CORNEAL TISSUE IS EXTREMELY LIMITED (ONLY 1 CORNEA IS AVAILABLE FOR EVERY 70 NEEDED WORLDWIDE), AND THE RISKS OF DONOR TISSUE FAILURE (IMMEDIATE RISK) AND GRAFT REJECTION AND FAILURE (LIFETIME RISKS) ARE SIGNIFICANT. IN ADDITION TO PRESERVING SIGHT AND CIRCUMVENTING THE NEED FOR SURGICAL INTERVENTION, MEDICAL THERAPY (E.G., EYE DROPS) WOULD AVOID THE FOLLOWING KEY ISSUES: 1) HIGH MEDICAL COSTS, 2) LACK OF AVAILABLE CORNEAS, 3) LOST PRODUCTIVITY COSTS, AND 4) LONG-TERM CARE COSTS ASSOCIATED WITH CORNEAL TRANSPLANTATION. THE NEE
Timeline
No timeline articles for this company yet.